PROLIXIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prolixin, and when can generic versions of Prolixin launch?
Prolixin is a drug marketed by Apothecon and Bristol Myers Squibb and is included in five NDAs.
The generic ingredient in PROLIXIN is fluphenazine enanthate. There are nineteen drug master file entries for this compound. Additional details are available on the fluphenazine enanthate profile page.
Summary for PROLIXIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 1 |
Patent Applications: | 3,820 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROLIXIN at DailyMed |
Recent Clinical Trials for PROLIXIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre for Addiction and Mental Health | Phase 2 |
Canadian Institutes of Health Research (CIHR) | Phase 2 |